Gastrointestinal Malignancies

Share

Program Content

Activities

  • Conference to Clinic: Gastrointestinal Cancers
    Conference to Clinic: Gastrointestinal Cancers
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 20, 2023

  • Conference to Clinic: Gastrointestinal Malignancies
    Conference to Clinic: Expert Analysis of the Top Gastrointestinal Malignancies Abstracts From the 2023 Oncology Meeting in Chicago
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 29, 2023

    Expires: June 28, 2024

  • ASCO 2023 GI Cancers
    Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2023 ASCO Annual Meeting
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 29, 2023

    Expires: August 28, 2024

Activities

ATTRACTION-5
ATTRACTION-5: Phase III Study of Adjuvant Nivolumab + Chemotherapy After Gastrectomy for Pathologic Stage III Gastric or Gastroesophageal Junction Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

NORPACT-1
NORPACT-1: Neoadjuvant FOLFIRINOX vs Upfront Surgery in Resectable Pancreatic Head Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

KEYNOTE-966 HRQoL
KEYNOTE-966: Health-Related Quality-of-Life Outcomes With Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy in Advanced Biliary Tract Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2023

Zanidatamab for HER2+ BTC
HERIZON-BTC-01: Zanidatamab, a HER2-Targeted Bispecific Antibody, in Previously Treated HER2‑Amplified Biliary Tract Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

Tucatinib + Trastuzumab in HER2+ BTC
Tucatinib + Trastuzumab for Previously Treated Advanced HER2+ Biliary Tract Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

AtezoTRIBE Update
AtezoTRIBE: Updated Results of First-line Treatment With FOLFOXIRI + Bevacizumab ± Atezolizumab for Unresectable Metastatic Colorectal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

PROSPECT
PROSPECT: Neoadjuvant Chemoradiation vs FOLFOX With Selective Chemoradiation for Locally Advanced Rectal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

FIRE-4 Liquid Biopsy Analysis
FIRE-4: RAS/BRAF Mutation by Liquid Biopsy and Benefit From First-line FOLFIRI + Cetuximab in Patients With RAS-WT Metastatic Colorectal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2023

Faculty

cover img faculity

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

cover img faculity

Rachna Shroff, MD, MS, FASCO

Interim Executive Council Member, Clinical Affairs for the University of Arizona Cancer Center
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Professor of Medicine
University of Arizona College of Medicine
Tucson, Arizona

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp., Novocure, and Seagen.

Merck Sharp & Dohme Corp.

Novocure

Seagen